Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
Más filtros











Intervalo de año de publicación
1.
Adv Drug Deliv Rev ; 207: 115198, 2024 04.
Artículo en Inglés | MEDLINE | ID: mdl-38341146

RESUMEN

Gene therapy is one of the most advanced therapies in current medicine. In particular, interference RNA-based therapy by small interfering RNA (siRNA) has gained attention in recent years as it is a highly versatile, selective and specific therapy. In dermatological conditions, topical delivery of siRNA offers numerous therapeutic advantages, mainly by inhibiting the expression of target transcripts directly in the skin. However, crossing the stratum corneum and overcoming intracellular barriers is an inherent challenge. Substantial efforts by scientists have moved towards the use of multimodal and multifunctional nanoparticles to overcome these barriers and achieve greater bioavailability in their site of action, the cytoplasm. In this review the most innovative strategies based on nanoparticle and physical methods are presented, as well as the design principles and the main factors that contribute to the performance of these systems. This review also highlights the synergistic contributions of medicine, nanotechnology, and molecular biology to advancing translational research into siRNA-based therapeutics for skin diseases.


Asunto(s)
Nanopartículas , Enfermedades de la Piel , Humanos , ARN Interferente Pequeño , Interferencia de ARN , Terapia Genética/métodos , Preparaciones Farmacéuticas , Enfermedades de la Piel/tratamiento farmacológico , Nanotecnología
2.
Pharmaceutics ; 16(1)2024 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-38258088

RESUMEN

This work aimed to develop a three-dimensional (3D) wearable drug-loaded earring tap to treat affections caused by aesthetic perforations. The initial phase involved a combination of polymers to prepare filaments for fused deposition modeling (FDM) 3D printing using a centroid mixture design. Optimized filament compositions were used in the second phase to produce 3D printed earring taps containing the anti-inflammatory naringenin. Next, samples were assessed via physicochemical assays followed by in vitro skin permeation studies with porcine ear skin. Two filament compositions were selected for the study's second phase: one to accelerate drug release and another with slow drug dissolution. Both filaments demonstrated chemical compatibility and amorphous behavior. The use of the polymer blend to enhance printability has been confirmed by rheological analysis. The 3D devices facilitated naringenin skin penetration, improving drug recovery from the skin's most superficial layer (3D device A) or inner layers (3D device B). Furthermore, the devices significantly decreased transdermal drug delivery compared to the control containing the free drug. Thus, the resulting systems are promising for producing 3D printed earring taps with topical drug delivery and reinforcing the feasibility of patient-centered drug administration through wearable devices.

3.
Pharmaceutics ; 15(7)2023 Jul 21.
Artículo en Inglés | MEDLINE | ID: mdl-37514188

RESUMEN

Nanotechnology has been investigated for treatments of hair follicle disorders mainly because of the natural accumulation of solid nanoparticles in the follicular openings following a topical application, which provides a drug "targeting effect". Despite the promising results regarding the therapeutic efficacy of topically applied nanoparticles, the literature has often presented controversial results regarding the targeting of hair follicle potential of nanoformulations. A closer look at the published works shows that study parameters such as the type of skin model, skin sections analyzed, employed controls, or even the extraction methodologies differ to a great extent among the studies, producing either unreliable results or precluding comparisons altogether. Hence, the present study proposes to review different skin models and methods for quantitative and qualitative analysis of follicular penetration of nano-entrapped drugs and their influence on the obtained results, as a way of providing more coherent study protocols for the intended application.

4.
J Funct Biomater ; 14(7)2023 Jul 17.
Artículo en Inglés | MEDLINE | ID: mdl-37504869

RESUMEN

Small interfering RNA (siRNA) molecules have limited transfection efficiency and stability, necessitating the use of delivery systems to be effective in gene knockdown therapies. In this regard, lipid-polymeric nanocarriers have emerged as a promising class of nanoparticles for siRNA delivery, particularly for topical applications. We proposed the use of solid lipid-polymer hybrid nanoparticles (SLPHNs) as topical delivery systems for siRNA. This approach was evaluated by assessing the ability of SLPHNs-siRNA complexes to internalize siRNA molecules and both to penetrate skin layers in vitro and induce gene knocking down in a skin cell line. The SLPHNs were formed by a specific composition of solid lipids, a surfactant polymer as a dispersive agent, and a cationic polymer as a complexing agent for siRNA. The optimized nanocarriers exhibited a spherical shape with a smooth surface. The average diameter of the nanoparticles was found to be 200 nm, and the zeta potential was measured to be +20 mV. Furthermore, these nanocarriers demonstrated excellent stability when stored at 4 °C over a period of 90 days. In vitro and in vivo permeation studies showed that SLPHNs increased the cutaneous penetration of fluorescent-labeled siRNA, which reached deeper skin layers. Efficacy studies were conducted on keratinocytes and fibroblasts, showing that SLPHNs maintained cell viability and high cellular uptake. Furthermore, SLPHNs complexed with siRNA against Firefly luciferase (siLuc) reduced luciferase expression, proving the efficacy of this nanocarrier in providing adequate intracellular release of siRNA for silencing specific genes. Based on these results, the developed carriers are promising siRNA delivery systems for skin disease therapy.

5.
Molecules ; 28(3)2023 Feb 02.
Artículo en Inglés | MEDLINE | ID: mdl-36771111

RESUMEN

Achieving the best possible outcome for the therapy is the main goal of a medicine. Therefore, nanocarriers and co-delivery strategies were invented to meet this need, as they can benefit many diseases. This approach was applied specifically for cancer treatment, with some success. However, these strategies may benefit many other clinical issues. Skin is the largest and most exposed organ of the human body, with physiological and psychological properties. Due to its exposition and importance, it is not difficult to understand how many skin diseases may impact on patients' lives, representing an important burden for society. Thus, this review aims to summarize the state of the art in research concerning nanocarriers and co-delivery strategies for topical agents' applications targeting skin diseases. The challenge for the medicine of the future is to deliver the drug with spatial and temporal control. Therefore, the co-encapsulation of drugs and the appropriate form of administration for them are so important and remain as unmet needs.


Asunto(s)
Nanopartículas , Enfermedades de la Piel , Humanos , Preparaciones Farmacéuticas/metabolismo , Piel/metabolismo , Absorción Cutánea , Enfermedades de la Piel/metabolismo , Sistemas de Liberación de Medicamentos , Portadores de Fármacos/metabolismo , Administración Cutánea , Administración Tópica
6.
Colloids Surf B Biointerfaces ; 208: 112101, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34517218

RESUMEN

This study proposes developing a topical formulation based on poly-ε-caprolactone (PCL) or methacrylic acid/methyl methacrylate copolymer (EL100) nanoparticles to enable a safer and more effective therapy of alopecia and acne with spironolactone. The effect of the size of the nanoparticle on follicular-targeted drug delivery is also verified. Compatibility studies based on thermal analyses and complementary techniques showed a small interaction of the drug with excipients, which may not compromise the drug stability. PCL nanoparticles of 180.0 ±â€¯1.6 and 126.8 ±â€¯1.0 nm, and EL100 nanoparticles of 102.7 ±â€¯7.1 nm were then prepared. All nanoparticles entrapped more than 75 % of spironolactone, were physically stable, and stabilized the drug for at least 90 days. They were also non-irritant according to HET-CAM tests. Drug release from the nanoparticles was reduced in aqueous buffer media but fast when in contact with oil. Finally, in vitro skin penetration experiments revealed the largest nanoparticles (of 180 nm) targeted drug delivery to the hair follicles 5-fold (p < 0.05) more than the control solution, 2.1-fold (p < 0.05) more than nanoparticles produced with the same polymer (PCL) but with smaller size (123 nm), and 4.9-fold (p < 0.05) more than the 102-nm E100 nanoparticles. In conclusion, follicular targeting can be adjusted according to nanoparticle size, and this work succeeded in obtaining polymeric nanoparticles adequate to enable topical treatment of acne and alopecia with spironolactone.


Asunto(s)
Portadores de Fármacos , Nanopartículas , Sistemas de Liberación de Medicamentos , Tamaño de la Partícula , Poliésteres , Polímeros , Espironolactona
7.
J Control Release ; 338: 316-329, 2021 10 10.
Artículo en Inglés | MEDLINE | ID: mdl-34437914

RESUMEN

Psoriasis is a chronic inflammatory skin disease that presents increased expression of tumor necrosis factor α (TNFα), a proinflammatory cytokine. The discovery of RNA interference (RNAi), mediated by short interfering RNA (siRNA), made it possible for the expression of some genes to be eliminated. However, for its application, it is necessary to use carriers that can protect siRNA and release it in the target cells. Herein, we developed a delivery system for siRNA based on hybrid polymer-lipid nanoparticles (PLNs) and combined this system with photochemical internalization (PCI), photoactivating the photosensitizer TPPS2a, to optimize the endosomal escape of TNFα siRNA in the cytoplasm, aiming to use the system as a topical formulation to treat psoriasis. The PLNs composed of 2.0% of Compritol® 888 ATO (lipid), 1.5% of poloxamer 188 and 0.1% of the cationic polymer poly(allylamine hydrochloride) showed an average nanoparticle size of 142 nm, a zeta potential of +25 mV, and the ability to efficiently coencapsulate TPPS2a and complexed siRNA. In addition, these materials did not present cellular toxicity and showed high cellular uptake. In vitro delivery studies using porcine skin model revealed that the PLNs delivered siRNA and TPPS2a into the skin. The efficacy was verified using an in vivo psoriasis animal (hairless mouse) model induced by imiquimod (IMQ) cream. The results revealed that PLN-TPPS2a-TNFα siRNA combined with PCI resulted in a decrease in the levels of TNFα, showing the efficiency of the treatment to silence this cytokine in psoriatic lesions, which was accompanied by a reduction in the redness and scaling of the mouse skin. The results showed the potential of the developed PLNs in combined silencing gene therapy and PCI for topical treatment of psoriasis.


Asunto(s)
Nanopartículas , Psoriasis , Animales , Imiquimod , Ratones , Psoriasis/tratamiento farmacológico , Psoriasis/genética , ARN Interferente Pequeño , Factor de Necrosis Tumoral alfa
8.
Curr Drug Targets ; 22(10): 1090-1107, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33397257

RESUMEN

Photodynamic Therapy (PDT) is a therapeutic modality used for several malignant and premalignant skin disorders, including Bowen's disease skin cancers and Superficial Basal Cell Carcinoma (BCC). Several photosensitizers (PSs) have been explored for tumor destruction of skin cancers, after their activation by a light source of appropriate wavelength. Topical release of PSs avoids prolonged photosensitization reactions associated with systemic administration; however, its clinical usefulness is influenced by its poor tissue penetration and the stability of the active agent. Nanotechnology-based drug delivery systems are promising tool to enhance the efficiency for PDT of cancer. This review focuses on PSs encapsulated in nanocarriers explored for PDT of skin tumors.


Asunto(s)
Enfermedad de Bowen , Carcinoma Basocelular , Portadores de Fármacos , Nanopartículas , Fotoquimioterapia , Neoplasias Cutáneas , Ácido Aminolevulínico/uso terapéutico , Enfermedad de Bowen/tratamiento farmacológico , Carcinoma Basocelular/tratamiento farmacológico , Humanos , Fármacos Fotosensibilizantes/uso terapéutico , Neoplasias Cutáneas/tratamiento farmacológico
9.
Int J Nanomedicine ; 15: 8075-8095, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33116519

RESUMEN

PURPOSE: Sonodynamic therapy (SDT) is a new therapeutic modality for the noninvasive cancer treatment based on the association of ultrasound and sonosensitizer drugs. Topical SDT requires the development of delivery systems to properly transport the sonosensitizer, such as zinc phthalocyanine (ZnPc), to the skin. In addition, the delivery system itself can participate in sonodynamic events and influence the therapeutic response. This study aimed to develop ZnPc-loaded micelle to evaluate its potential as a topical delivery system and as a cavitational agent for low-frequency ultrasound (LFU) application with the dual purpose of promoting ZnPc skin penetration and generating reactive oxygen species (ROS) for SDT. METHODS: ZnPc-loaded micelles were developed by the thin-film hydration method and optimized using the Quality by Design approach. Micelles' influence on LFU-induced cavitation activity was measured by potassium iodide dosimeter and aluminum foil pits experiments. In vitro skin penetration of ZnPc was assessed after pretreatment of the skin with LFU and simultaneous LFU treatment using ZnPc-loaded micelles as coupling media followed by 6 h of passive permeation of ZnPc-loaded micelles. The singlet oxygen generation by LFU irradiation of the micelles was evaluated using two different hydrophilic probes. The lipid peroxidation of the skin was estimated using the malondialdehyde assay after skin treatment with simultaneous LFU using ZnPc-loaded micelles. The viability of the B16F10 melanoma cell line was evaluated using resazurin after treatment with different concentrations of ZnPc-loaded micelles irradiated or not with LFU. RESULTS: The micelles increased the solubility of ZnPc and augmented the LFU-induced cavitation activity in two times compared to water. After 6 h ZnPc-loaded micelles skin permeation, simultaneous LFU treatment increased the amount of ZnPc in the dermis by more than 40 times, when compared to non-LFU-mediated treatment, and by almost 5 times, when compared to LFU pretreatment protocol. The LFU irradiation of micelles induced the generation of singlet oxygen, and the lipoperoxidation of the skin treated with the simultaneous LFU was enhanced in three times in comparison to the non-LFU-treated skin. A significant reduction in cell viability following treatment with ZnPc-loaded micelles and LFU was observed compared to blank micelles and non-LFU-treated control groups. CONCLUSION: LFU-irradiated mice can be a potential approach to skin cancer treatment by combining the functions of increasing drug penetration and ROS generation required for SDT.


Asunto(s)
Indoles/farmacología , Micelas , Compuestos Organometálicos/farmacología , Ultrasonido , Aluminio/química , Animales , Supervivencia Celular/efectos de los fármacos , Humanos , Isoindoles , Melanoma/tratamiento farmacológico , Melanoma/patología , Melanoma Experimental/patología , Fosfatidiletanolaminas/química , Fármacos Fotosensibilizantes/farmacología , Polietilenglicoles/química , Yoduro de Potasio/química , Oxígeno Singlete/química , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Porcinos , Compuestos de Zinc
10.
Drug Deliv Transl Res ; 10(6): 1810-1828, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-32803561

RESUMEN

In this study, the development and the performance of a new targeted liquid crystalline nanodispersion (LCN) by the attachment of cell-penetrating peptides (CPP) onto their surfaces to improve skin delivery of lipoic acid (LA) were evaluated. For that, the synthesis and characterization of this new platform as well as its spatiotemporal analysis from in vitro and in vivo topical application were explored and extensively discussed in this paper. The TAT or D4 peptides were chosen as CPP due to specific target strategies by the charge grouping on the skin surface or target the overexpressed epidermal growth factor receptor (EGFR) of cell membrane of keratinocytes, respectively. Thus, the nanoparticle characterization results when taken together suggested that designed LCNs maintained their hexagonal phase structure, nanoscale particle size, and low polydispersity index even after drug, lipopolymers, and peptide additions, which are proved to be favorable for topical skin delivery. There were no statistical differences among the LCNs investigated, except for superficial charge of LCN conjugated with TAT which may have altered the LCN zeta potential due to cationic charge of TAT amino acid sequence compared with D4. The cumulative amounts of LA retained into the skin were determined to be even higher coming from the targeted LCNs. Moreover, the exogenous antioxidant application of the LA from the LCNs can prevent ROS damage, which was demonstrated by this study with the less myeloperoxidase (MPO) activity and decrease in cytokine levels (TNF-alpha and IL-1ß) generated by the oxidative stress modulation. Together, the data presented highlights the potential of these targeted LCNs, and overall, opens new frontiers for preclinical trials.


Asunto(s)
Antiinflamatorios , Péptidos de Penetración Celular , Nanopartículas , Piel/efectos de la radiación , Ácido Tióctico , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacología , Masculino , Ratones , Absorción Cutánea , Ácido Tióctico/administración & dosificación , Ácido Tióctico/farmacología , Rayos Ultravioleta
11.
Int J Pharm ; 582: 119336, 2020 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-32304728

RESUMEN

Excessive exposure to solar radiation induces injurious effects on human skin. Our previous study evidenced that protocatechuic acid (P0) and ethyl protocatechuate (P2) act against photodamage and photoaging. The present study aimed to develop solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for topical delivery of P0 or P2, as a strategy for photoprotection. Lipid nanoparticles exhibited mean particle size, polydispersity index, zeta potential and association efficiency between 200 and 400 nm, 0.160 to 0.460, -2.2 to -5.2 mV, and 60% to 80%, respectively. The formulations were stable for 3 months when stored at 4○C and 25○C/60% RH. SLNs/NLCs-P0 showed minor cytotoxicity effects compared with SLNs/NLCs-P2, in HaCat (keratinocytes) and HFF-1 (fibroblasts) cell lines. Additionally, bare NLCs exhibited less cytotoxicity effect, compared with bare SLNs. NLCs exhibited a controlled in vitro release of P0 and P2, and were able to protect the compounds against UVB degradation. Ex vivo permeability study showed that NLCs modulated P0 and P2 retention profiles on human skin layers. Furthermore, histological analysis of skin showed that NLCs-P0 did not cause morphological alterations, while NLCs-P2 showed a potential irritation effect in the skin structure. Based on these results, NLCs were considered a potential dermatological nanocarrier for P0 delivery.


Asunto(s)
Portadores de Fármacos , Hidroxibenzoatos/administración & dosificación , Lípidos/química , Nanopartículas , Protectores Solares/administración & dosificación , Línea Celular , Supervivencia Celular/efectos de los fármacos , Preparaciones de Acción Retardada , Composición de Medicamentos , Estabilidad de Medicamentos , Femenino , Humanos , Hidroxibenzoatos/química , Hidroxibenzoatos/metabolismo , Hidroxibenzoatos/toxicidad , Lípidos/toxicidad , Masculino , Permeabilidad , Piel/metabolismo , Absorción Cutánea , Protectores Solares/química , Protectores Solares/metabolismo , Protectores Solares/toxicidad , Rayos Ultravioleta
12.
Mater Sci Eng C Mater Biol Appl ; 110: 110639, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32204073

RESUMEN

In this study, we developed a water-in-oil microemulsion containing vitamin A (retinol) and vitamin E (α-tocopherol), which serves as a multifunctional nanosystem that co-delivers antioxidants and displayed additive effect against acute skin inflammation. Microemulsion (ME) was prepared by mixing a surfactant blend (Tween 80 and propylene glycol, 5:1) with isopropyl myristate and water (ratio of 50:40:10, respectively). Vitamin A (0.05% w/w concentration) and/or vitamin E (0.1% w/w concentration) were incorporated into the surfactant mixture of ME by stirring with a magnetic stirrer for 30 min. This multifunctional ME displayed physical stability, with low cytotoxicity in 3T3 cell line, as well as cellular internalization into the cytosol. In vivo treatments using ME delivering α-tocopherol reduced dermal expression of TNF-α by 1.3-fold (p < 0.01), when compared to unloaded ME treatment group. When retinol was added into the ME containing α-tocopherol, it further reduced TNF-α expression by 2-fold (p < 0.001), suggesting the additive effect of vitamin E and vitamin A in the treatment against skin inflammation. In conclusion, we successfully developed the use of water-in-oil ME to pack both vitamin E and vitamin A, and demonstrated for the first time its anti-inflammatory potential when applied topically to TPA-induced inflamed skin.


Asunto(s)
Sistemas de Liberación de Medicamentos , Inflamación/tratamiento farmacológico , Inflamación/patología , Piel/patología , Vitamina A/administración & dosificación , Vitamina E/administración & dosificación , Enfermedad Aguda , Administración Tópica , Animales , Rastreo Diferencial de Calorimetría , Supervivencia Celular/efectos de los fármacos , Emulsiones , Células HaCaT , Humanos , Ratones , Ratones Pelados , Células 3T3 NIH , Piel/efectos de los fármacos , Porcinos , Vitamina A/farmacología , Vitamina A/uso terapéutico , Vitamina E/farmacología , Vitamina E/uso terapéutico
13.
Int J Biol Macromol ; 154: 1265-1275, 2020 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-31726173

RESUMEN

Tumors located in the oral mucosa are challenging to treat since surgery can lead to aesthetic, speech, and salivation problems, radiotherapy alone is often ineffective, and systemic chemotherapy brings meaningful side effects to the patient. Here, we proposed to develop mucoadhesive chitosan nanoparticles entrapping the chemotherapeutic oxaliplatin (OXPt) and to evaluate ex vivo its penetration in porcine mucosa under both passive and iontophoretic topical treatments. OXPt-loaded chitosan nanoparticles presented a small hydrodynamic size (188 ± 20 nm), narrow distribution (PDI of 0.28 ± 0.02) and positive zeta potential (+44.8 ± 2.8 mV). These nanoparticles provided a "burst effect" on drug release followed by a longer-term controlled release. When applied to the oral mucosa, the chitosan nanoparticles increased 3-fold drug penetration, and this rate was maintained even when the mucosa was "washed" with a buffer to mimic salivation. Iontophoresis doubled the amount of OXPt transported to the mucosa. These amounts exceeded the dose required to cause cell death of an oral tumor cell line. Besides, chitosan nanoparticles increased the rate of cells that entered into apoptosis. In summary, this study points to the feasibility of topical therapy with chitosan nanoparticles, potentialized by the application of iontophoresis, to treat oral tumors.


Asunto(s)
Quitosano/química , Portadores de Fármacos/química , Neoplasias de la Boca/tratamiento farmacológico , Membrana Mucosa/química , Nanopartículas/química , Oxaliplatino/administración & dosificación , Oxaliplatino/química , Adhesividad , Administración Tópica , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Liberación de Fármacos , Humanos , Hidrodinámica , Iontoforesis , Oxaliplatino/uso terapéutico , Porcinos
14.
Nanomedicine (Lond) ; 14(16): 2243-2267, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-31411537

RESUMEN

Aging, exposure to oxidants, infectious pathogens, inflammogens, ultraviolet radiation and other environmental and genetic factors can result in the development of various skin disorders. Despite immense progress being made in dermatological treatments, many skin-associated problems still remain difficult to treat and various therapies have limitations. Progress in silica-based nanomaterials research provides an opportunity to overcome these drawbacks and improve therapies and is a promising tool for inclusion in clinical practice to treat skin diseases. This review focuses on the use of various types of silica nanoparticles with therapeutic applications in various skin disorders. These nanosystems improve treatment efficacy by maintaining or enhancing the effect of several drugs and are useful tools for nanomedicine, pharmaceutical sciences and future clinical applications.


Asunto(s)
Nanomedicina/métodos , Dióxido de Silicio/química , Piel/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Humanos , Nanopartículas/química , Nanoestructuras/química , Nanotecnología/métodos , Piel/efectos de la radiación , Rayos Ultravioleta , Cicatrización de Heridas/fisiología
15.
Curr Pharm Des ; 25(4): 455-466, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30947656

RESUMEN

The first limiting barrier for the transport in the skin is the stratum corneum; different strategies have been developed to overcome this barrier, including chemical enhancers. However, these penetration enhancers have limitations, including toxic adverse effects. In this context, research into nanomaterials has provided new tools to increase the residence time of drugs by generating a reservoir, increasing the specificity of drugs and reducing their adverse effects, and improving the penetration of drugs that are difficult to formulate. Silica nanoparticles have been proposed as suitable nanocarriers for skin delivery. Unfortunately, the mechanisms involved in the interaction, transport and fate of silica nanoparticles in the skin have not been fully investigated. This paper reviews significant findings about the interaction between silica-based nanocarriers and the skin. First, this review focuses on the properties and functions of the skin, the skin penetration properties of silica nanoparticles, their synthesis strategies and their toxicity. Finally, advances and evidence on the application of silica nanocarriers in skin drug delivery are provided, in which the use of nanoparticles increases the stability and solubility of the bioactive compound, enhancing its performance, act as penetrator enhancer and improving controlled release. Thus, improving the treatment of some skin disorders.


Asunto(s)
Sistemas de Liberación de Medicamentos , Nanopartículas/administración & dosificación , Dióxido de Silicio/administración & dosificación , Absorción Cutánea , Piel/efectos de los fármacos , Administración Cutánea , Animales , Portadores de Fármacos , Humanos
16.
Int J Pharm ; 560: 365-376, 2019 Apr 05.
Artículo en Inglés | MEDLINE | ID: mdl-30772460

RESUMEN

In spite of the high incidence of breast cancer worldwide, there are few strategies for its chemoprevention, and they have limited adherence mainly due to their serious adverse effects. As a new approach for local breast cancer chemoprevention, we developed and optimized microemulsions for topical delivery of celecoxib to the breast skin, and evaluated their combination with microneedles to improve drug penetration for localization in the mammary tissue. Microemulsions containing water at 15% (ME-15), 29% (ME-29) and 60% (ME-60) were obtained and characterized. They were isotropic, displayed Newtonian behavior and particle size smaller than 100 nm. ME-15 and ME-29 increased transepidermal water loss (TEWL) compared to ME-60, and displayed stronger vascular toxicity, evidenced by hemorrhage and lysis in HET-CAM assays. ME-60 was more efficacious at increasing celecoxib cutaneous and percutaneous delivery (1.3-4-fold). Increasing the number of microneedle roller applications from 1 to 8 increased the number of skin punctures and TEWL; its association with ME-60 promoted no further increase in TEWL, but improved (1.6-4-fold) celecoxib cutaneous and percutaneous delivery. Microemulsion incorporation reduced celecoxib IC50 in MCF-7 cells (3.3-fold), suggesting that presence of formulation components in the mammary tissue might improve drug cytotoxicity.


Asunto(s)
Neoplasias de la Mama/tratamiento farmacológico , Celecoxib/administración & dosificación , Sistemas de Liberación de Medicamentos , Absorción Cutánea , Administración Cutánea , Animales , Celecoxib/farmacocinética , Celecoxib/farmacología , Química Farmacéutica/métodos , Quimioprevención/métodos , Inhibidores de la Ciclooxigenasa 2/administración & dosificación , Inhibidores de la Ciclooxigenasa 2/farmacocinética , Inhibidores de la Ciclooxigenasa 2/farmacología , Emulsiones , Femenino , Humanos , Concentración 50 Inhibidora , Células MCF-7 , Agujas , Tamaño de la Partícula , Porcinos
17.
J Pharm Biomed Anal ; 161: 273-279, 2018 Nov 30.
Artículo en Inglés | MEDLINE | ID: mdl-30176524

RESUMEN

A preformulation study with finasteride (FIN) was conducted to enable the development of a topical matrix system to treat androgenic alopecia. The compatibility of the drug with hidroxypropyl-ß-cyclodextrin (HPßCD) and the hydrophilic polymers Klucel EXF (KLU) and Soluplus (SOL) were evaluated according to a simplex centroid mixture design. An extensive analytical arsenal was used to encompass the stability of the drug in the different mixtures. The selected excipients showed to have intense thermal interaction with FIN, which was dependent on the composition of the sample, shifting FIN melting peak to reduced temperatures along with the decrease of its associated enthalpy. The mixture design allowed measuring the interactions between components, showing that KLU enhanced the ability of the drug to form inclusion complexes with HPßCD, while SOL exhibited the opposite effect. The stability of samples was preserved even after a thermal treatment used to simulate pharmaceutical processing. Indeed, no drug content decaying was observed, which corroborates the chemical stability of the systems as indicated by thermogravimetry, chromatographic, morphological and spectroscopic assays. The original crystalline phase of the drug (orthorhombic form I) did not change after the heating treatment of the samples, demonstrating its physical stability. Thus, these series of experiments may guide the development of delivery systems for topical use of FIN, showing which combinations and proportions of components can lead to better results in terms of stability and drug delivery.


Asunto(s)
2-Hidroxipropil-beta-Ciclodextrina/química , Sistemas de Liberación de Medicamentos/métodos , Finasterida/química , Polímeros/química , Administración Tópica , Estabilidad de Medicamentos , Excipientes/química , Finasterida/administración & dosificación , Calor , Interacciones Hidrofóbicas e Hidrofílicas
18.
Colloids Surf B Biointerfaces ; 164: 281-290, 2018 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-29413607

RESUMEN

Wound healing involves the integration of biological and molecular events and, in case of chronic wounds, the use of drugs can be associated to side effects. Therefore, there is a search for alternatives therapeutics that encompass minimal toxicity. The use of natural compounds is an attractive approach for treating inflammatory disorders, wounds and burns. In this context, thymol has antimicrobial, antioxidant and antiseptic properties and is a promising compound in wound healing and inflammation management. However, essential oils and their constituents such as thymol present high volatility and can also easily decompose, thereby the encapsulation of these compounds into nanoparticles may be an efficient approach to modulate the release of the active ingredient, to increase the physical stability and to eventually reduce the toxicity. The aims of this work were to encapsulate thymol in nanostructured lipid carriers (NLCs) composed of natural lipids and assess its in vivo anti-inflammatory and antipsoriatic activity. The carrier containing thymol was produced by sonication method and showed 107.7 (±3.8) nm of size, zeta potential of -11.6 (±2.9) mV and entrapment efficiency of 89.1 (±4.2)%. Thymol-NLCs were incorporated into a gel and the final formulation presented rheological characteristics and pH suitable for topic application. In addition, the gel containing thymol-NLCs was tested in vivo on two different mouse models of skin inflammation, showing anti-inflammatory activity. Finally, this formulation was tested in an imiquimod-induced psoriasis mouse model and showed improved healing, compared to negative control. Therefore, thymol-NLCs is an interesting formulation for future treatment of inflammatory skin diseases.


Asunto(s)
Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Lípidos/química , Nanopartículas/química , Timol/administración & dosificación , Timol/uso terapéutico , Administración Tópica , Aminoquinolinas/efectos adversos , Animales , Antiinflamatorios/farmacología , Antioxidantes/farmacología , Betametasona/administración & dosificación , Betametasona/farmacología , Betametasona/uso terapéutico , Muerte Celular/efectos de los fármacos , Línea Celular , Supervivencia Celular/efectos de los fármacos , Modelos Animales de Enfermedad , Composición de Medicamentos , Liberación de Fármacos , Oído/patología , Edema/inducido químicamente , Edema/tratamiento farmacológico , Edema/patología , Humanos , Imiquimod , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Inflamación/patología , Queratinocitos/efectos de los fármacos , Queratinocitos/patología , Ratones Endogámicos BALB C , Tamaño de la Partícula , Permeabilidad , Psoriasis/inducido químicamente , Psoriasis/tratamiento farmacológico , Reología , Piel/efectos de los fármacos , Sus scrofa , Timol/farmacología
19.
Curr Drug Deliv ; 15(7): 1064-1071, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29318970

RESUMEN

BACKGROUND: PnPP-19 is a 19-amino-acid synthetic peptide previously described as a novel drug for the treatment of erectile dysfunction. OBJECTIVE: The aim of this work was to evaluate the physicochemical properties of cationic transfersomes containing PnPP-19 and the skin permeation of free PnPP-19 and PnPP-19-loaded transfersomes. METHODS: Three different liposomal preparation methods were evaluated. Cationic transfersomes contained egg phosphatidyl choline: stearylamine (9:1 w/w) and Tween 20 (84.6:15.4 lipid:Tween, w/w). Lipid concentration varied from 20 to 40 mM. We evaluated the entrapment percentage, mean diameter, zeta potential and stability at 4 °C of the formulations. The skin permeation assays were performed with abdominal human skin using Franz diffusion cell with 3 cm2 diffusion area at 32 °C and a fluorescent derivative of the peptide, containing 5-TAMRA, bound to PnPP-19 C-terminal region, where an extra lysine was inserted. RESULTS: Our results showed variable entrapment efficiencies, from 6% to 30%, depending on the preparation method and the lipid concentration used. The reverse phase evaporation method using a total lipid concentration equal to 40 mM led to the best entrapment percentage (30.2 + 4.5%). Free PnPP-19 was able to permeate skin at a rate of 10.8 ng/cm2/h. However, PnPP-19 was specifically hydrolyzed by skin proteases, generating a fragment of 15 amino acid residues. Encapsulated PnPP-19 permeated the skin at a rate of 19.8 ng/cm2/h. CONCLUSION: The encapsulation of PnPP-19 in cationic transfersomes protected the peptide from degradation, favoring its topical administration.


Asunto(s)
Péptidos/administración & dosificación , Péptidos/química , Absorción Cutánea , Administración Cutánea , Adulto , Aminas/administración & dosificación , Aminas/química , Disfunción Eréctil/tratamiento farmacológico , Femenino , Humanos , Técnicas In Vitro , Liposomas , Masculino , Persona de Mediana Edad , Fosfatidilcolinas/administración & dosificación , Fosfatidilcolinas/química , Polisorbatos/administración & dosificación , Polisorbatos/química , Rodaminas/administración & dosificación , Rodaminas/química , Piel/metabolismo
20.
Curr Med Chem ; 25(5): 606-635, 2018 Feb 13.
Artículo en Inglés | MEDLINE | ID: mdl-28990515

RESUMEN

The cutaneous route is attractive for the delivery of drugs in the treatment of a wide variety of diseases. However the stratum corneum (SC) is an effective barrier that hampers skin penetration. Within this context, liposomes emerge as a potential carrier for improving topical delivery of therapeutic agents. In this review, we aimed to discuss key aspects for the topical delivery by drug-loaded liposomes. Phospholipid type and phase transition temperature have been shown to affect liposomal topical delivery. The effect of surface charge is subject to considerable variation depending on drug and composition. In addition, modified vesicles with the presence of components for permeation enhancement, such as surfactants and solvents, have been shown to have a considerable effect. These liposomes include: Transfersomes, Niosomes, Ethosomes, Transethosomes, Invasomes, coated liposomes, penetration enhancer containing vesicles (PEVs), fatty acids vesicles, Archaeosomes and Marinosomes. Furthermore, adding polymeric coating onto liposome surface could influence cutaneous delivery. Mechanisms of delivery include intact vesicular skin penetration, free drug diffusion, permeation enhancement, vesicle adsorption to and/or fusion with the SC, trans-appendageal penetration, among others. Finally, several skin conditions, including acne, melasma, skin aging, fungal infections and skin cancer, have benefited from liposomal topical delivery of drugs, with promising in vitro and in vivo results. However, despite the existence of some clinical trials, more studies are needed to be conducted in order to explore the potential of liposomes in the dermatological field.


Asunto(s)
Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/uso terapéutico , Liposomas/administración & dosificación , Liposomas/uso terapéutico , Enfermedades de la Piel/tratamiento farmacológico , Administración Cutánea , Animales , Portadores de Fármacos/síntesis química , Portadores de Fármacos/química , Humanos , Liposomas/síntesis química , Liposomas/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA